Predicting Survival in Patients with Advanced NSCLC Treated with Atezolizumab Using Pre‐ and on‐Treatment Prognostic Biomarkers
Clinical Pharmacology & Therapeutics · 2024
DOI: 10.1002/cpt.3371 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Sébastien Benzekry und 11 weiteren Autor:innen. Beteiligte Einrichtung: COMPutational Pharmacology and Clinical Oncology Department, Centre Inria de l'Université Côte d'Azur, Cancer Research Center of Marseille, Inserm UM…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Antibodies, Monoclonal, Humanized, Lung Neoplasms, Machine Learning. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Existing survival prediction models rely only on baseline or tumor kinetics data and lack machine learning integration. We introduce a novel kinetics‐machine learning (kML) model that integrates baseline markers, tumor kinetics, and four on‐treatment simple blood markers (albumin, C‐reactive protein, lactate dehydrogenase, and neutrophils). Developed for immune‐checkpoint inhibition (ICI) in non‐small cell lung cancer on three phase II trials (533 patients), kML was validated on the two arms of a phase III trial (ICI and chemotherapy, 377 and 354 patients). It outperformed the current state‐of‐the‐art for individual predictions with a test set C‐index of 0.790, 12‐months survival accuracy of 78.7% and hazard ratio of 25.2 (95% CI: 10.4–61.3, P < 0.0001) to identify long‐term survivors. Critically, kML predicted the success of the phase III trial using only 25 weeks of on‐study data (predicted HR = 0.814 (0.64–0.994) vs. final study HR = 0.778 (0.65–0.931)). Modeling on‐treatment blood markers combined with predictive machine learning constitutes a valuable approach to support personalized medicine and drug development. The code is publicly available at https://gitlab.inria.fr/benzekry/nlml_onco .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- COMPutational Pharmacology and Clinical Oncology Department, Centre Inria de l'Université Côte d'Azur, Cancer Research Center of Marseille, Inserm UMR1068, CNRS UMR7258, Aix Marseille University UM105, Marseille, France.
- Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center Basel, Basel, Switzerland.
- Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center Zurich, Zurich, Switzerland.
- Pharma Research and Early Development, Data & Analytics, Roche Innovation Center Basel, Basel, Switzerland.
- Modeling and Simulation, Clinical Pharmacology, Genentech Research and Early Development, Marseille, France.
- Modeling and Simulation, Clinical Pharmacology, Genentech Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland.
ORCID-Profile: Sébastien Benzekry, Rene Bruno, François Mercier, Candice Jamois
Zitieren
APA
Benzekry, S., Karlsen, M., Bigarré, C., Kaoutari, A. E., Gomes, B., Stern, M., Neubert, A., Bruno, R., Mercier, F., Vatakuti, S., Curle, P., & Jamois, C. (2024). Predicting Survival in Patients with Advanced NSCLC Treated with Atezolizumab Using Pre‐ and on‐Treatment Prognostic Biomarkers. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3371
Vancouver
Benzekry S, Karlsen M, Bigarré C, Kaoutari AE, Gomes B, Stern M, et al. Predicting Survival in Patients with Advanced NSCLC Treated with Atezolizumab Using Pre‐ and on‐Treatment Prognostic Biomarkers. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3371
BibTeX
@article{Benzekry2024,
author = {Benzekry, Sébastien and Karlsen, Mélanie and Bigarré, Célestin and Kaoutari, Abdessamad El and Gomes, Bruno and Stern, Martin and Neubert, Ales and Bruno, Rene and Mercier, François and Vatakuti, Suresh and Curle, Peter and Jamois, Candice},
title = {Predicting Survival in Patients with Advanced NSCLC Treated with Atezolizumab Using Pre‐ and on‐Treatment Prognostic Biomarkers},
journal = {Clinical Pharmacology & Therapeutics},
year = {2024},
doi = {10.1002/cpt.3371}
}
EUVIMED